Bear Stalking Biotech Sector
The biotech sector saw a significant run-up last month, but for at least one analyst, questions remain about what the second half holds.
India needs a body like FDA for quality control in drugs
The health ministry has decided to set up an autonomous drug control authority on the lines of the US Food and Drugs Administration, but with a mandate going far beyond the latter.
U.S. relatively hospitable to stem-cell research
The United States appears to be a relatively hospitable place for embryonic stem cell research, especially compared to Canada and some nations in Europe where governments not only refuse financial support for human cloning to produce stem cells, they outlaw the practice.
Drug firms don't disclose enough
The editor-in-chief of the New England Journal of Medicine accused three of the largest drug companies of ‘making a mockery‘ of efforts to create transparency in clinical trials, adding that could lead some important medical publications to avoid publishing their studies.
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments